222 related articles for article (PubMed ID: 16548127)
1. Close up on atomoxetine: a nonstimulant choice for treating ADHD.
Allen C; Pitcock J
Adv Nurse Pract; 2006 Mar; 14(3):39-40, 42-3, 78. PubMed ID: 16548127
[No Abstract] [Full Text] [Related]
2. Drugs for treatment of ADHD.
Treat Guidel Med Lett; 2006 Nov; 4(51):77-82. PubMed ID: 17039210
[No Abstract] [Full Text] [Related]
3. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
5. Improving decision making in the treatment of ADHD.
Vitiello B
Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
[No Abstract] [Full Text] [Related]
6. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
Harpin VA
Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
[TBL] [Abstract][Full Text] [Related]
7. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
[TBL] [Abstract][Full Text] [Related]
8. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Sasané R; Hodgkins P; Meijer W
Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
Corman SL; Fedutes BA; Culley CM
Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
[TBL] [Abstract][Full Text] [Related]
10. The MTA at 8.
Pliszka SR
J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1122. PubMed ID: 19855222
[No Abstract] [Full Text] [Related]
11. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
12. Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.
Kratochvil CJ; Faries D; Vaughan B; Perwien A; Busner J; Saylor K; Kaplan S; Buermeyer C; Swindle R
J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):51-62. PubMed ID: 17343553
[TBL] [Abstract][Full Text] [Related]
13. [Atomoxetine in ADHD: caution].
Karila L
Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
[No Abstract] [Full Text] [Related]
14. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
[TBL] [Abstract][Full Text] [Related]
16. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
[TBL] [Abstract][Full Text] [Related]
19. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
20. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Jaworowski S; Benarroch F; Gross-Tsur V
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
